Status:
COMPLETED
"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Renal Transplant
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to see if campath-1H can be used in first time renal transplant subjects to prevent rejection and reduce the overall amount of anti-rejection medications that patients take...
Detailed Description
Twenty nine primary recipients of either a live donor or deceased donor renal transplant were enrolled in this study. Subjects were administered two 20mg doses of Campath-1H antibody therapy (Day 0 an...
Eligibility Criteria
Inclusion
- primary renal transplant (not HLA identical)
- ages 18-60 years
Exclusion
- recipient panel reactive antibody level \>10%
- recipient of a DCD kidney
- no prior organ transplant
- no multi-organ transplant recipient
- no subject who is currently receiving systemic corticosteroids
- no pregnant or lactating subjects
- no history of Hepatitis B, C or HIV positivity
- no recipient of a kidney with cold ischemia time \>36 hours
Key Trial Info
Start Date :
August 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00365846
Start Date
August 1 2000
End Date
July 1 2006
Last Update
October 3 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53792